

Supplementary Table S3: Clinical data of jIIM patients' subgroups.

	jIIM	DM	ASyS Jo-1	ASyS PL-7	OM
Number of patients	15 (100 %)	9 (60%)	2 (13%)	2 (13%)	2 (13%)
Age at biopsy in years	8,7 ± 4,4	8,2 ± 4,1	4,5 ± 2,1	12 ± 7,1	12 ± 1,4
Range in years	3 - 17	3 - 16	3 - 6	7 - 17	11 - 13
female	11/15 (73%)	8/9 (89%)	1/2 (50%)	2/2 (100%)	0/2 (0%)
Skeletal muscle symptoms	14/15 (93 %)	9/9 (100%)	1/2 (50%)	2/2 (100%)	2/2 (100%)
Myalgia	11 (73 %)	8 (89%)	0 (0%)	1 (50%)	2 (100%)
Exercise induced myalgia	6 (40 %)	5 (56%)	0 (0%)	1 (50%)	0 (0%)
Proximal weakness	14 (93 %)	9 (100%)	1 (50%)	2 (100%)	2 (100%)
Skin symptoms	15/15 (100 %)	9/9 (100%)	2/2 (100%)	2/2 (100%)	2/2 (100%)
Dry skin	6 (40 %)	3 (33%)	0 (0%)	1 (50%)	2 (100%)
Exanthema	3 (20 %)	2 (22%)	0 (0%)	1 (50%)	0 (0%)
Erythema	4 (27 %)	3 (33%)	0 (0%)	1 (50%)	0 (0%)
Butterfly rash	5 (33 %)	3 (33%)	0 (0%)	1 (50%)	1 (50%)
Redness, livid colouration	8 (53 %)	5 (56%)	2 (100%)	0 (0%)	1 (50%)
Raynaud's phenomenon	1 (7 %)	0 (0%)	0 (0%)	0 (0%)	1 (50%)
Gotttron's papules	8 (53 %)	3 (33%)	2 (100%)	2 (100%)	1 (50%)
Nail fold changes	1 (7 %)	1 (11%)	0 (0%)	0 (0%)	0 (0%)
Calcinosis	4 (27 %)	2 (22%)	1 (50%)	0 (0%)	1 (50%)
Accompanying symptoms	15/15 (100 %)	9/9 (100%)	2/2 (100%)	2/2 (100%)	2/2 (100%)
Fever	3 (20 %)	2 (22%)	0 (0%)	1 (50%)	0 (0%)
Difficulty swallowing	1 (7 %)	1 (11%)	0 (0%)	0 (0%)	0 (0%)
Morning stiffness	1 (7 %)	1 (11%)	0 (0%)	0 (0%)	0 (0%)
Arthritis	1 (7 %)	1 (11%)	0 (0%)	0 (0%)	0 (0%)
Weight gain	2 (13 %)	2 (22%)	0 (0%)	0 (0%)	0 (0%)
Weight loss	1 (7 %)	0 (0%)	1 (50%)	0 (0%)	0 (0%)
Night sweat	1 (7 %)	1 (11%)	0 (0%)	0 (0%)	0 (0%)
Oedema	3 (20 %)	3 (33%)	0 (0%)	0 (0%)	0 (0%)
Lymphadenopathy	1 (7 %)	0 (0%)	0 (0%)	0 (0%)	1 (50%)
Fatigue / concentration difficulties	7 (47 %)	3 (33%)	1 (50%)	1 (50%)	1 (50%)
	1 (7 %)	1 (11%)	0 (0%)	0 (0%)	0 (0%)

Loss of appetite/ rejection to drink	5 (33 %)	3 (33%)	1 (50%)	1 (50%)	0 (0%)
Sadness / mood slump/ mood swings	3 (20 %)	3 (33%)	0 (0%)	0/2 (0%)	0/2 (0%)
Social withdrawal					
Extramuscular symptoms	6/15 (40 %)	5/9 (56%)	1/2 (50%)	0/2 (0%)	0/2 (0%)
Pulmonary restriction	2 (13 %)	2 (22%)	0 (0%)	0 (0%)	0 (0%)
Pneumonia	1 (7 %)	1 (11%)	0 (0%)	0 (0%)	0 (0%)
Cardial involvement	4 (27 %)	3 (33%)	1 (50%)	0 (0%)	0 (0%)
Comorbidities	5/15 (33 %)	3/9 (33%)	0/2 (0%)	1/2 (50%)	1/2 (50%)
Cystic fibrosis	1 (7 %)	0 (0%)	0 (0%)	1 (50%)	0 (0%)
Factor-V-Leiden mutation	1 (7 %)	1 (11%)	0 (0%)	0 (0%)	0 (0%)
Hypothyroidism	1 (7 %)	0 (0%)	0 (0%)	0 (0%)	1 (50%)
Steatosis hepatis	1 (7 %)	1 (11%)	0 (0%)	0 (0%)	0 (0%)
HLA-B27 enthesitis	1 (7 %)	1 (11%)	0 (0%)	0 (0%)	0 (0%)
Laboratory results	15/15	9/9	2/2	2/2	2/2
Creatine kinase (CK) ↑	(100%)	(100%)	(100%)	(100%)	(100%)
Lactate dehydrogenase (LDH) ↑	14 (93 %)	8 (89%)	2 (100%)	2 (100%)	2 (100%)
GOT ↑	11 (73 %)	7 (78%)	1 (50%)	2 (100%)	1 (50%)
GPT ↑	11 (73 %)	6 (67%)	2 (100%)	2 (100%)	1 (50%)
	7 (47 %)	3 (33%)	1 (50%)	2 (100%)	1 (50%)
MRI skeletal muscle	11/15	5/9 (56%)	2/2	2/2	2/2
Normal	(73 %)	0 (0%)	(100%)	(100%)	(100%)
Oedema	2 (18 %)	4 (44%)	0 (0%)	1 (50%)	1 (50%)
Enhancement of contrast medium / signal alterations	6 (54 %)	2 (22%)	1 (50%)	0 (0%)	1 (50%)
Compatible with myositis	4 (36 %)		1 (50%)	1 (50%)	0 (0%)
		4/9 (44%)			
Musculoskeletal	8/11 (73 %)	6/9 (67%)	2/2	1/2 (50%)	1/2 (50%)
Ultrasound	9/15 (60 %)	2/9 (22%)	(100%)	1/2 (50%)	0/2 (0%)
Oedema	3/9 (33 %)	4/9 (44%)	2/2	1/2 (50%)	0/2 (0%)
	6/9 (67 %)		(100%)	1/2 (50%)	0/2 (0%)

Enhancement of echogenicity / signal alterations	6/9 (67 %)	3/9 (33%)	0/2 (0%)		
	11/15	7/9 (78%)	1/2 (50%)	1/2 (50%)	0/2 (0%)
Compatible with myositis	(73 %)	7/9 (78%)		2/2	2/2
Electromyography (EMG)			2/2	(100%)	(100%)
Myopathic, compatible with myositis	8/11 (72 %)	0/9 (0%)	(100%)	0/2 (0%)	1/2 (50%)
Unspecific sign	3/11 (27 %)		0/2 (0%)		
			0/2 (0%)	2/2 (100%)	1/2 (50%)
			0/2 (0%)		